SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
5.53
+0.25 (4.73%)
At close: Mar 6, 2026, 4:00 PM EST
5.54
+0.01 (0.18%)
After-hours: Mar 6, 2026, 7:59 PM EST
SLS Employees
SELLAS Life Sciences Group had 15 employees as of December 31, 2024. The number of employees decreased by 1 or -6.25% compared to the previous year.
Employees
15
Change (1Y)
-1
Growth (1Y)
-6.25%
Revenue / Employee
n/a
Profits / Employee
-$1,729,467
Market Cap
941.66M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Valneva SE | 700 |
| MannKind | 592 |
| Arvinas | 246 |
| Geron | 229 |
| Sana Biotechnology | 194 |
| ARS Pharmaceuticals | 167 |
| Cullinan Therapeutics | 111 |
SLS News
- 3 days ago - What's Going With SELLAS Life Sciences Stock On Wednesday? - Benzinga
- 7 weeks ago - SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe - GlobeNewsWire
- 2 months ago - SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 3 months ago - SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 - GlobeNewsWire
- 4 months ago - SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript - Seeking Alpha
- 4 months ago - SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds - GlobeNewsWire
- 7 months ago - Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026 - Seeking Alpha
- 7 months ago - SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification - GlobeNewsWire